Oligometastatic Prostate Cancer
Open Access
- 27 October 2016
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 17 (12) , 1-8
Abstract
Opinion statement The mainstay of treatment for men with three or fewer non-castrate metastatic lesions outside of the prostate remains morbid palliative androgen deprivation therapy. We believe there is now a significant body of retrospective literature to suggest a survival benefit if these men have radical treatment to their primary tumour alongside ‘metastasis-directed therapy’ to the metastatic deposits. However, this regimen should be reserved to high-volume centres with quality assurance programmes and excellent outcomes. Patients should be made clear as to the uncertainty of benefit for this multi-site treatment strategy, and we await the publication of randomised controlled trials reporting in the next 5 years.Keywords
Funding Information
- University of Oxford
This publication has 45 references indexed in Scilit:
- Stereotactic body radiotherapy for oligometastasesThe Lancet Oncology, 2013
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METNature Medicine, 2012
- Oligometastases revisitedNature Reviews Clinical Oncology, 2011
- Surgical management of lymph‐node‐positive prostate cancer: improves symptomatic controlBJU International, 2010
- The Number of Pulmonary Metastases: Influence on Practice and OutcomeJournal of Thoracic Oncology, 2010
- Use of Surgery Among Elderly Patients With Stage IV Colorectal CancerJournal of Clinical Oncology, 2004
- Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermiaThe Lancet Oncology, 2004
- Impact of Previous Local Treatment for Prostate Cancer on Subsequent Metastatic DiseaseJournal of Urology, 2002
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomasCancer, 1995